GoAI
Get started
Connect Biopharma Holdings Limited logo

Connect Biopharma Holdings Limited

CNTB

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.36

+$0.08 · +3.51%

Aug 21, 4:00 PM ET

Pre-market

$2.41

+$0.05 · +2.12%

Aug 24, 5:31 AM ET

CNTB company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

27

Expensive

Momentum

67

Gaining

Sentiment

68

Bullish

Risk resilience

42

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Barry D. Quart
Listed since
Mar 19, 2021
Employees
64

Market position

Day range

Current $2.36

52-week range

Current $2.36

Open
$2.30
Previous close
$2.28
Volume
444.95K
1.22× average
Average volume
364.48K
Average daily volume
Market cap
148.59M USD
Beta
-0.22
Market reference 1
50-day average
$2.2375
+5.47% above average
200-day average
$2.4486
-3.62% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
119.31M USD
P/E (TTM)
-2.68×
P/B (TTM)
5.52×
P/S (TTM)
50.59×
EV / EBITDA
-2.19×
Earnings yield
-35.35%
Free cash flow yield
-32.90%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-1795.61%
Net margin
-1763.40%
Return on equity
-132.16%
Return on assets
-98.94%
Return on invested capital
-135.74%

Financial health

Debt / equity
0.02×
Current ratio
3.74×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends9184%-27152%-63488%-99825%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2024: -86.24%Operating margin, FY2025: -90740.63%Net margin, FY2024: -60.03%Net margin, FY2025: -86687.50%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2024 -86.24%. Operating margin FY2025 -90740.63%. Net margin FY2024 -60.03%. Net margin FY2025 -86687.50%.

Income trends

Revenue

64K USD-99.75%

Operating income

−58.07M USD-158.66%

Net income

−55.48M USD-255.00%
Income trends across reported periods48.86M USD−42.46M USD−133.78M USD−225.1M USDRevenue, FY2024: 26.03M USDRevenue, FY2025: 64K USDOperating income, FY2021: −98.11M USDOperating income, FY2022: −119.32M USDOperating income, FY2023: −69.06M USDOperating income, FY2024: −22.45M USDOperating income, FY2025: −58.07M USDNet income, FY2021: −202.27M USDNet income, FY2022: −118.09M USDNet income, FY2023: −62.11M USDNet income, FY2024: −15.63M USDNet income, FY2025: −55.48M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 26.03M USD. Revenue FY2025 64K USD. Operating income FY2021 −98.11M USD. Operating income FY2022 −119.32M USD. Operating income FY2023 −69.06M USD. Operating income FY2024 −22.45M USD. Operating income FY2025 −58.07M USD. Net income FY2021 −202.27M USD. Net income FY2022 −118.09M USD. Net income FY2023 −62.11M USD. Net income FY2024 −15.63M USD. Net income FY2025 −55.48M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue64K USD26.03M USD———
Gross profit64K USD26.03M USD———
Research and development37.8M USD29.26M USD53M USD96.63M USD80.5M USD
Selling, general, and administrative20.34M USD19.23M USD16.05M USD20.81M USD19.01M USD
Operating expenses58.14M USD48.49M USD69.06M USD119.32M USD98.11M USD
Interest income2.27M USD4.45M USD5.2K USD1.56M USD97.67K USD
Interest expense———21.03K USD6.91K USD
Depreciation and amortization704K USD660K USD720K USD1.03M USD634K USD
Operating income−58.07M USD−22.45M USD−69.06M USD−119.32M USD−98.11M USD
Net income−55.48M USD−15.63M USD−62.11M USD−118.09M USD−202.27M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
70%
7 beats, 3 misses, 0 met estimates
Average EPS surprise
+35.64%
10 comparable reports
Latest EPS result
-0.27
Estimate -0.31 · Beat by 14.26%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.02-0.14-0.26-0.38Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual -0.058, estimate -0.26, surprise +77.86%, Beat. Q2 2025, reported May 15, 2025: actual -0.026, estimate -0.26, surprise +89.93%, Beat. Q3 2025, reported Aug 13, 2025: actual -0.032, estimate -0.22, surprise +85.42%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.044, estimate -0.034, surprise -29.69%, Miss. Q1 2026, reported Mar 31, 2026: actual -0.27, estimate -0.3, surprise +10.00%, Beat. Q2 2026, reported May 12, 2026: actual -0.34, estimate -0.29, surprise -17.24%, Miss. Q3 2026, reported Aug 12, 2026: actual -0.27, estimate -0.315, surprise +14.26%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.27, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates22.57M15.05M7.52M457.3Q1 '25MissQ2 '25EstimateQ3 '25BeatQ4 '25EstimateQ1 '26EstimateQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 31, 2025: actual 260.1K USD, estimate 20.9M USD, surprise -98.76%, Miss. Q2 2025, reported May 15, 2025: actual —, estimate 48K USD, surprise —, Comparison unavailable. Q3 2025, reported Aug 13, 2025: actual 48K USD, estimate 21.3K USD, surprise +125.35%, Beat. Q4 2025, reported Nov 12, 2025: actual —, estimate 4.91K USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual —, estimate 538 USD, surprise —, Comparison unavailable. Q2 2026, reported May 12, 2026: actual 24.42K USD, estimate 743.31K USD, surprise -96.71%, Miss. Q3 2026, reported Aug 12, 2026: actual 2.75M USD, estimate 743.31K USD, surprise +269.69%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate 114.59K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

5 ratings
Strong buy00%
Buy5100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

4 institutions
Piper SandlerupgradeNeutralOverweight
Cantor FitzgeraldmaintainOverweight

CNTB news

globenewswire.com

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD – – Expect to report topline results from both Phase 2 Seabreeze STAT studies in September 2026 – – Cash runway expected…

Read source
defenseworld.net

Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the firm, MarketBeat reports. One…

Read source
seekingalpha.com

Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent

CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which…

Read source
globenewswire.com

Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into…

Read source

CNTB peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CNTB

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
865.54K
Weight
0.01%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
862.12K
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
174.28K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
115.75K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
19.8K
Weight
0.00%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
16.75K
Weight
—
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$117.49+0.86%
iShares Russell 2500 ETF logoiShares Russell 2500 ETFSMMD
Market value
16.74K
Weight
0.00%
AUM
3.85B USD
Expense ratio
0.23%
Price / 1D
$91.86+0.58%
Vanguard Russell 2000 Value ETF logoVanguard Russell 2000 Value ETFVTWV
Market value
13.09K
Weight
0.00%
AUM
1.4B USD
Expense ratio
0.06%
Price / 1D
$198.38+0.34%

Continue in GoAI

Research CNTB

research.disclaimer